873P Nivolumab (NIVO) in the First-Line (1L) or Second-Line (2L) and Later (2L+) Settings in Patients (pts) with Recurrent And/or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Updated Results from the German Non-Interventional Study (NIS), HANNA
Annals of Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined